Home›Trial›NCT06433765
NCT06433765RECRUITING

A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

Study Summary

The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.

Conditions
Multiple Sclerosis
Interventions / Drugs
No intervention
View on ClinicalTrials.gov ↗
Sponsor
TGTX
TG Therapeutics
Oncology
D37/100
Study Details
Enrollment728 participants
Primary Completion—
Lead SponsorTG Therapeutics, Inc.
Data Retrieved2026-04-11 04:29:09.138007+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 728 participants
Sponsor Catalyst Profile

TG Therapeutics (TGTX) is the sponsoring company for this trial. BiotechSign currently grades this company D (37/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

TGTX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.